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Abstract
Background: It was well known that the clinical use of chemotherapeutic drugs is restricted by severe adverse reactions and
drug resistances. Thus it is necessary to figure out a strategy to increase the specific anti-tumor efficiency of
chemotherapeutic drugs. Apigenin, a kind of flavonoids, has been reported to possess anticancer activities with very low
cytotoxicity to normal tissue.
Methodology/Principal Findings: Our results from cell viability assay, western-blots and TdT-mediated dUTP-biotin nick
end labeling (TUNEL) assay demonstrated the synergistic pro-apoptotic effects of a low dose of apigenin and paclitaxel in
human cancer cell lines. To analyze the underlying mechanism, we examined reactive oxygen species (ROS) staining after
cells were treated with a combination of apigenin and paclitaxel, or each of them alone. Data from flow-cytometry showed
that superoxides but not reduction of peroxides accumulated in HeLa cells treated with apigenin or a combination of
apigenin and paclitaxel. Apigenin and paclitaxel-induced HeLa cell apoptosis was related to the level of ROS in cells. We
further evaluated activity and protein level of superoxide dismutase (SOD). Apigenin significantly inhibited SOD activity but
did not alter the SOD protein level suggesting that apigenin promoted ROS accumulation through suppressing enzyme
activity of SOD. Addition of Zn
2+,C u
2+ and Mn
2+ to cell lysates inhibited apigenin’s effects on SOD activity. At the same time,
data from caspase-2 over-expression and knocked-down experiments demonstrated that caspase-2 participated in apigenin
and paclitaxel-induced HeLa cell apoptosis.
Conclusions/Significance: Taken together, our study demonstrated that apigenin can sensitize cancer cells to paclitaxel
induced apoptosis through suppressing SOD activity, which then led to accumulation of ROS and cleavage of caspase-2,
suggesting that the combined use of apigenin and paclitaxel was an effective way to decrease the dose of paclitaxel taken.
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Introduction
Chemotherapy is one of the most widely employed treatments
for cancer. However many chemotherapeutic drugs can produce
unpleasant side effects,especially when taken in high doses. One
of the chemotherapeutic drugs, paclitaxel, a mitotic inhibitor,
may lead to hypersensitivity reactions [1], neutropenia [2],
neurotoxicity [3], cardiac rhythm disorder [4] and other
miscellaneous toxic effects [5], which seriously worsens the
quality of life of cancer patients and results in dosage reduction
and discontinuation of treatment. It is therefore important to
decrease the adverse side effects of chemotherapeutic agents in
clinical treatment of cancer. In addition, drug resistance in
clinical therapy often interferes with the efficiency of chemother-
apeutic agents.
Reactive oxygen species (ROS) including superoxide radical,
hydrogen peroxide (H2O2), hydroxyl radical, nitric oxide, and
various nitric oxide-derived reactive nitro species (RNS) are
formed as natural byproducts of normal metabolism of oxygen
in human cells and tissues. Because of their highly reactive
character, they tend to become involved in unwanted reactions
that cause damage to cells and ultimately lead to diseases.
Cancer cells exhibit increased glycolysis in combination with a
reduced rate of respiration and these alterations in metabolism
have been shown to be associated with enhanced oxidative
stress [6–8]. A high cell redox status could stimulate tumor
formation through creating an enhanced cell-proliferative
environment, inducing DNA damage, and turning off tumor
suppression functions [9,10]. Tumor growth and migration
could be inhibited in vitro by alteration of the environment
around tumor cells to a more reducing one. In opposition to
this, a high cell redox state would also support increased
apoptosis, which would inhibit tumor formation. Thus, in
cancer cells, the high redox state could enhance their tolerance
to environmental stresses and chemotherapeutic drugs. Tumor
cells expressed a higher level of MnSOD indicate a poor
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ability to process caspase-2 [13,14] which is an initiator caspase
led to mitochondrial membrane permeabilization [15] and is
also an important member in apoptosis signal amplification
loop [16]. Besides, previous studies in caspase-2 knocked-out
mice have shown that caspase-2 activation was related with
ROS accumulation [17]. Reduced apoptosis rate was also
detected in caspase-2
2/2 oocytes [18].
Apigenin (49, 5, 7-trihydroxyflavone) is widely contained in
many fruits and vegetables. Recently, it was reported that apigenin
had a potential anti-tumor effects on several human cancer cell
lines with low cytotoxicity and no mutagenic activity. [19–21].
Apigenin could enhance the intracellular accumulation of ROS
and had the pro-oxidant potential [22,23] and decrease SOD
activity in lung cancer cells [24].
In the present work, we demonstrated that apigenin could
sensitize cancer cells to paclitaxel induced apoptosis through
suppressing SOD activity and leading to accumulation of ROS
and cleavage of caspase-2, suggesting the combined use of
apigenin and paclitaxel was effective for cancer therapy.
Materials and Methods
Cell culture and transfection
Human cervical epithelial carcinoma cell line HeLa, human
lung epithelial carcinoma cell line A549, human negroid
hepatocyte carcinoma cell line Hep3B, and human embryonic
kidney 293A (HEK293A) cells obtained from Institute of
Biochemistry and Cell Biology, Chinese Academy of Sciences
(Shanghai, P.R. China), were maintained in Dulbecco’s
modified Eagle’s medium (Invitrogen) containing 10% fetal calf
serum (Hyclone) and antibiotics (100 mg/ml penicillin and
100 mg/ml streptomycin) with 5% CO2 at 37uC. Transient
transfection was performed with a modified calcium phosphate
method or by using the Lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions. In all cases, the
total amount of DNA was normalized by the empty control
plasmids.
Antibodies, regents and DNA constructs
Mouse monoclonal antibody against Flag-tag was purchased
from Sigma. Rabbit polyclonal antibodies against poly ADP-ribose
polymerase (PARP), caspase-3 and b–actin were obtained from
Cell Signaling Technology. Mouse polyclonal antibody against
caspase-2 came from Santa Cruz Biotechnology. Rabbit poly-
clonal antibodies against cleaved caspase-3 came from Bioworld
Technology, Inc. Mouse monoclonal antibody against SOD1 and
rabbit polyclonal antibodies against SOD2, Endo G and AIF were
obtained from Abcam. Caspase-2 inhibitor benzyloxycarbonyl-
Val-Asp (OMe)-Val-Ala-Asp(OMe)-fluorom ethylketone (z-
VDVAD-fmk) was obtained from Calbiochem. ROS detection
reagents (CM-H2DCFDA and dihydroethidium (DHE)) and
apoptotic detecting regent (FITC-Annexin V and propidium
iodide buffer) were from Molecular Probes
TM (Invirogen).
Dimethyl sulfoxide was from Amresco. Apigenin, paclitaxel and
DETC were purchased from Sigma.
pcDNA3.1-flag-caspase2 (WT) and pRNAU6-caspase2 were
constructed by using standard techniques. pcDNA3.1 was digested
with XhoI and KpnI. The primers (sense:TTTTCTCGAGAC-
CATGGACTACAAGGACGACGATGATAAGGCGGCGCC-
GAGCGCGGGGT, anti-sense: ATATGGTACCTCATGTGG-
GAGGGTGTCCTG) were designed to generate pcDNA3.1-flag-
caspase2 (WT). Caspase-2 (NM_032982.2) gene was synthesized by
Invitrogen. pRNAU6 was digested with Bam HI and Hind III,
and the annealed targeting oligonucleotides ACAGCTGTTGTT-
GAGCGAA for caspase-2 was ligated into the vector [25].
Cell viability and TUNEL assay
To evaluate paclitaxel-induced cytotoxicity, Colorimetric Cy-
totoxic 96 nonradioactive cytotoxicity assay (Promega) was
performed according to the manufacturer’s protocol. The cell
viability was detected by measuring endogenous lactate dehydro-
genase quantitatively.
TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay
was performed in HeLa cells by using GuavaH TUNEL Kit as
previously described [26]. The cells were detected on a Guava
EasyCyte
TM System, and data were analyzed by using Guava
TUNEL Software (Guava Technologies, Hayward, CA, USA). All
assays were performed for three replicates.
Annexin V/PI assay
Annexin V/PI assay, by using annexin V/PI double staining of
unfixed cells, distinguishes between early apoptotic cells and late
apoptotic/necrotic cells. Both floated and attached cells were
suspended in 500 ml binding buffer (10 mM HEPES, 140 mM
NaCl, 2.5 mM CaCl2, 0.1% BSA). Annexin V-FITC (5 mL) and
PI (5 mL) was then added into each sample. After 15 min
incubation in the dark, the flow cytometric analysis was carried
out using the Guava EasyCyte
TM System. For each sample 5000
cells were analyzed. Data were analyzed by using Guava TUNEL
Software (Guava Technologies, Hayward, CA, USA).
ROS detection
HeLa cells were seeded in 6-well plates and after 24 h, cells
were incubated with ROS specific dyes, dihydroethidium (DHE,
5 mM) or CM-H2DCFDA (5 mM), for 30 minutes. Cells were
subsequently treated with apigenin (15 mM), paclitaxel (4 nM) or
both of them for another 30 minutes. ROS were detected by using
a Guava EasyCyte
TM and analyzed with the Guava Express Pro
Software (Guava Technologies, Hayward, CA, USA). DHE was
detected under an emission within 580–583 nm (PM1) and CM-
H2DCFDA was detected under an emission of 525 nm (PM3).
Isolation of mitochondrion and Measurement of
mitochondrial membrane potential (MMP)
Intact mitochondrion was separated from cytosolic component
of HeLa cells for further protein analysis, using Mitochondria
Isolation Kit from Thermo-Pierce Dounce homogenization and
differential centrifugation were performed according to the
manufacturer’s protocol.
Mitochondrial membrane potential (MMP) of HeLa cells was
measured by using the Guava EasyCyte
TM MitoPotential Kit
(Guava Technologies, Hayward, CA, USA) as per the manufac-
turer’s instructions. Flourescence-based dye 5, 59,6 ,6 9-tetra-
chloro-1, 1 9,3 ,39-tetrethyl benzimidalyl carbocyanine iodide
(JC-1) was used to evaluate MMP changes. The cell impermeant
dye 7-AAD was used to simultaneously monitor cell membrane
permeability changes. Stained cells were analyzed on a Guava
EasyCyte
TM System.
Assay of superoxide dismutase activity
T h ee n z y m ea c t i v i t yo fS O Di nH e L ac e l l sw a sm e a s u r e db y
using commercial kits according to manufacturer’s protocol. In
this assay, the tetrazolium salt was utilized for detection of
superoxide radicals generated by xanthine oxidase and hypo-
xanthine. To measure MnSOD activity, cell lysates were
centrifuged at 10,0006g to separate MnSOD from CuZnSOD,
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cyanide.
RT-PCR analysis
Total RNA was extracted by using High Pure RNA Isolation
Kit (Roche) according to the protocol described by the manu-
facturer. RT-PCR was carried out using the M-MLV reverse
transcriptase (Invitrogen) with indicated primers (caspase-2, sense:
TTTTCTCGAGACCATGGACTACAAGGACGACGATGAT-
AAGGCGGCGCCGAGCGCGGGGT, anti-sense: ATATGGT-
ACCTCATGTGGGAGGGTGTCCTG; GAPDH, sense: CAT-
ATGGGGAAGGTGAAGGTCGGAGTC, anti-sense: GAATT-
CTTACTCCTTGGAGGCCATGTGG). PCR was performed at
Tm of 58uC for 30 cycles in reaction mixture of 25 mL
individually of each protein. PCR products were then resolved
on 1% agarose gels and stained with ethidium bromide. The house
keeping gene GAPDH was utilized as a control.
Western-blot analysis
Cell lysates were centrifuged (15,000 g) at 4uC for 15 min. The
Western blot analysis was performed as previously described [27].
The antibody–antigen complexes were visualized by the LI-COR
Odyssey Infrared Imaging System according to the manufacturer’s
instruction using IRDye800 flurophore-conjugated antibody (LI-
COR Biosciences, Lincoln, NE).
Determination of Synergism
The drug combination was determined by Chou-Talalay
method. The CI was calculated by the Chou-Talalay equation,
which takes into account both the potency (IC50 or Dm) and the
sharp of the dose-effect curve (m value) [28,29]. The classic
isobolgram (CI=1) is given by:
CI~
(D)1
(Dx)1
z
(D)2
(Dx)2
ðAÞ
In the denominators, (Dx)1 and (Dx)2 are the concentrations for D1
(apigenin) and D2 (paclitaxel) used alone that give x% inhibition,
whereas in the numerators, (D)1 and (D)2 are the doses of apigenin
and paclitaxel used in combination that isoeffectively inhibit x%.
CI,1, CI=1, and CI.1 suggest synergism, additive and
antagonism, respectively.
From the median-effect equation of Chou and Chou et al.
[29,30], the (Dx)1 and (Dx)2 can be readily calculated.
Dx~Dm½
fa
(1{fa)
 
1
m ðBÞ
Here Dm is the median-effect dose which obtained from the anti-
log of the X-intercept of the median-effect plot, X-log (D) versus
Y=log [fa/(12fa)] or Dm=10
2(Y2intercept)/m, and m is the slope of
the median-effect plot. Automated calculation of m, Dm,D x, and
CI values are also allowed with computer software.
Statistical analysis
Data was represented as mean6SD. Student’s t-test was applied
to analyze the statistical significance of variance pair-wise
comparison. In all analyses, P,0.05 was considered as statistically
significant.
Results
Combination treatment of apigenin with paclitaxel
significantly enhances cytotoxicity to human cancer cells
Since toxicity of paclitaxel is coupled to its antitumor activity
and apigenin has been reported to have antitumor activity with
low toxicity, we first observed the co-effects of comcination
paclitaxel with apigenin. HeLa cells were treated with various
doses of apigenin, paclitaxel or both of them and then the cell
viabilities were detected. As shown in Fig. 1A and B, both apigenin
and paclitaxel dose dependently induced cytotoxicity with
approximately 29% reduction of cell viability induced by apigenin
at the dose of 25 mM (Fig. 1A) and 24% reduction induced by
paclitaxel at the dose of 10 nM (Fig. 1B) respectively. When we
treated HeLa cells with 15 mM apigenin and 4 nM paclitaxel, over
50% decrease of cell viability was detected, nevertheless, less than
20% decrease of cell viability was observed in cells treated with
apigenin or paclitaxel respectively (Fig. 1C). We carried out Chou-
Talalay calculation to confirm the synergistic effects of apigenin
and paclitaxel on HeLa cells. The combination index (CI) was
0.391860.0436 at the dose of 15 mM apigenin and 4 nM
paclitaxel indicating synergistic effects of apigenin and paclitaxel.
These results indicated a significantly increased cytotoxicity when
apigenin and paclitaxel were administrated to HeLa cells
simultaneously. Also shown in Fig. 1C, combination of apigenin
with paclitaxel induced the similar results in the cancer cells other
than Hela cells including Hep3B and A549 cells. However, 15 mM
apigenin, 4 nM paclitaxel or combination of them did not result in
cytotoxicity to HEK293A cells respectively (Fig. 1C). These data
suggested there were synergistic effects of apigenin and paclitaxel
for specifically killing cancer cells
It has been reported that both paclitaxel [31,32] and apigenin
[21] can induce cell apoptosis. We next verify whether
combination use of apigenin and paclitaxel could induce more
acute apoptosis in HeLa cells. Compared to those groups treated
with apigenin or paclitaxel individually, apigenin and paclitaxel
co-treated groups showed more TUNEL positive staining cells.
The rates of TUNEL positive staining cells were notably increased
from 17.95% in paclitacel treated group and 19.65% of apigenin
treated group to around 40% in the groups treated by
combination of them (Fig. 1D). To quantify apoptosis, FACS
analysis was carried out after staining cells with FITC-annexin-V
Figure 1. Apigenin and paclitaxel enhance cytotoxicity to cancer cells compared with paclitaxel. A, HeLa cells were treated with
increased concentrations of apigenin (0–100 mM) for 24 hours. Cell vitality was measured. The experiment was independently repeated for three
times and data were shown as mean 6 SD. B, HeLa cells were treated with increased concentrations of paclitaxel (0–50 nM) for 24 hours. Cell vitality
was detected and analyzed as described in A. C, HeLa, A549, Hep3B and HEK293A cells were subjected to treatment with apigenin (15 mM)
combination with paclitaxel (4 nM) for 24 hours. Cell vitality was detected as described in A. D, HeLa cells were treated with apigenin or paclitaxel
respectively, besides, in other groups, apigenin was added to HeLa cells 2 hours before or after paclitaxel treatment, or apigenin and paclitaxel were
added to HeLa cells at the same time. TUNEL staining was performed and detected with a GuavaH TUNEL Kit. Numbers depicted the percentage of
TUNEL-positive cells. E, Cells were either left untreated or treated as previously described in D. At the indicated time, cells were stained with annexin
V/PI dye. Analyses were conducted on 5,000 cells in each trail. F, HeLa cells were treated with increased concentrations of apigenin or paclitaxel
respectively, or both of them for 24 hours. Then the cell lysates were subjected to Western blot to determine protein level of caspase-3 and PARP. V
represents vehicle (dimethyl sulfoxide). *p,0.05 compared with untreated group; **p,0.01 compared with untreated group.
doi:10.1371/journal.pone.0029169.g001
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the number of surviving cells decreased gradually after co-
treatment with apigenin and paclitaxel and only less than 60%
were survived 24 hours after apigenin and paclitaxel treatment.
Since activation of caspases is an important reason for apoptosis,
we further detected the cleavages of caspase-3 and PARP using
western blot analysis. As shown in Fig. 1F, both the cleavages of
caspase-3 and PARP were significantly enhanced by apigenin/
paclitaxel co-treatment compared with apigenin or paclitaxel
treatment alone. These results confirmed that apigenin/paclitaxel
co-treatment induced a significant apoptotic death of HeLa cells
suggesting that combination use of apigenin and paclitaxel would
produce a better anti-tumor effect than use of apigenin or
paclitaxel alone.
ROS produced by apigenin is essential for apigenin/
paclitaxel-induced HeLa cell apoptosis
Meanwhile flavonoids including apigenin were widely recog-
nized as the antioxidants, their pro-oxidant properties have also
been reported [33]. We speculated the anticancer effects of
combination apigenin/paclitaxel might be related with production
of ROS in HeLa cells induced by apigenin. Therefore we observed
the levels in HeLa cells treated with with apigenin, paclitaxel or
both of them. Two ROS-specific dyes, DHE and CM-H2DCFDA
displayed superoxide species and H2O2 in target cells respectively
[24]. CM-H2DCFDA is mainly oxidized by hydrogen peroxides
(H2O2) and hydroxyl radical, DHE is oxidized by superoxide
anions (O2
2). HeLa cells were stained with DHE and CM-
H2DCFDA followed by flow cytometry. As shown in Fig. 2, DHE-
specific ROS increased (Fig. 2A) whereas CM-H2DCFDA-specific
ROS reduced (Fig. 2B) in HeLa cells treated with apigenin within
the 30 minutes. No change was detected in the cells treated with
paclitaxel alone. A similar trend and a more significant change in
ROS’ status were observed in those cells treated with combination
of apigenin and paclitaxel compared with cells treated with
apigenin alone (Fig. 2). DHE staining observed in these
experiments resulted from the oxidation by superoxide species
suggesting that apigenin increased superoxide specie related ROS
in HeLa cells.
Next we evaluated whether apigenin/paclitaxel-induced apop-
tosis was dependent on ROS accumulation. N-acetyl-L-cysteine
(NAC), a well approved ROS scavenger, has been used to
antagonize the effect of ROS. Pretreatment of HeLa cells with
100 mM NAC effectively suppressed the generation of superoxide
species (Fig. 3A) and significantly inhibited the cell apoptosis
induced by apigenin and paclitaxel co-treatment (Fig. 3B). The
above data suggested that ROS were essential for apigenin/
paclitaxel-induced HeLa cell apoptosis.
Apigenin induces ROS accumulation through
suppressing the activity of SOD
We observed that after HeLa cells were treated with apigenin,
the abundance of superoxide species increased whereas H2O2
decreased. Considering SOD was a cellular enzyme which can
convert superoxide to H2O2, we speculated that apigenin might
reduce the activity of SOD and consequently led to the
accumulation of superoxide species. We then investigated the
effect of apigenin on protein level as well as the enzyme activity of
SOD. A significant suppression of both CuZnSOD (SOD1) and
MnSOD (SOD2) activity was observed in HeLa cells within
30 minutes after apigenin or apigenin/paclitaxel but not paclitaxel
treatment (Fig. 4A). However, there was no apparent change
observed in the protein level of CuZnSOD and MnSOD after
apigenin administration (Fig. 4B). Accordingly, it was evidential
that apigenin suppressed SOD activity and thus induced the
accumulation of ROS.
As above results showed that apigenin suppressed SOD activity,
and it had been reported that apigenin could form stable
complexation with metal ions in vitro [34], we thus determined if
apigenin could form complexation with metal ions and suppress
SOD activity through preventing SOD from assemble with its
cofactors. HeLa cells were treated with 15 mM apigenin for
30 minutes and the lysates of cells were incubated with 8 mMo f
ZnCl2 (aq), CuCl2 (aq) or MnCl2 (aq) respectively on ice for
another 30 minutes. The activity of SOD was measured using the
Cayman Superoxide Dismutase Assay Kit as described in Material
and Methods. As expected, apigenin significantly suppressed the
activities of both CuZnSOD and MnSOD, but the activity
CuZnSOD increased after Cu
2+,Z n
2+, and Mn
2+ exposure and
the activity of MnSOD also increased obviously after Mn
2+
exposure (Fig. 4C). Additionally, no significant change of SOD
activity was found when cell lysates were directly exposed to Cu
2+,
Zn
2+ or Mn
2+ without apigenin treatment (Fig. 4D), indicating
that these metal ions did not enhance basal SOD activity.These
results suggested that apigenin suppressed SOD activity probably
through forming a stable complexation with those metals in cells
[34], and apigenin might have higher binding affinity to Mn
2+.
SOD activity reduction is critical in apigenin/paclitaxel-
induced apoptosis
Apigenin inhibited the activity of SOD and combination of
apigenin/paclitaxel was more effective in inducing apoptosis of
cancer cells than each of them alone. In order to confirm that
apigenin-induced decrease of activity of SOD was critical in the
apoptosis triggered by apigenin/paclitaxel co-treatment, we
observed paclitaxel-induced apoptosis after blocking SOD enzyme
activity. DETC (diethylthiocarbamate), a well approved inhibitor
of both CuZnSOD and MnSOD was applied in our present study
[35]. As similar as apigenin, DETC suppressed the activity of
SOD and enhanced paclitaxel induced apoptosis as well (Fig. 5A).
These data strongly suggested that reduction of SOD activity by
apigenin is critical in the enhancement of paclitaxel-induced
apoptosis.
Activation of caspase-2 is important for apigenin/
paclitaxel-triggered HeLa cell apoptosis
Mitochondrial pathway plays an important role in ROS
triggered apoptosis [36,37] and caspase-2 has been considered as
the apical caspase in mitochondrial death signal amplification loop
[38,39]. ROS-induced caspase-2 cleavage and feedback amplifi-
cation of the apoptotic signal have also been investigated [40]. To
examine the effect of apigenin on mitochondrial pathway of
apoptosis, caspase-2 precursor cleavage was detected in apigenin-
treated HeLa cells by western-blot analysis. Co-treatment of HeLa
cells with apigenin and paclitaxel showed very low level of caspase-
2 precursor. When HeLa cells were pretreated with NAC, the
Figure 2. Apigenin induces ROS accumulation in HeLa cells. A, HeLa cells were treated with apigenin (15 mM) alone or together with
paclitaxel (4 nM), for indicated periods. DHE (5 mM) was added into cell cultures 30 minutes before the treatment. DHE staining in cells were detected
and analyzed by Guava EasyCyte
TM System. DHE staining in untreated cells were used as the negative control. B, CM-H2DCFDA (5 mM) staining was
performed and analyzed as described in A.
doi:10.1371/journal.pone.0029169.g002
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inhibitor z-VDVAD-fmk significantly reduced the cleavage of
caspase-3 and PARP in HeLa cells treated with apigenin
combined with paclitaxel (Fig. 5C). MMP may be a causal event
in precipitating apoptosis. The data in Fig. 5D indicated that
apigenin but not paclitaxel induced an increase of depolarization
of MMP suggesting the importance of apigenin in apigenin/
paclitaxel induced cancer cell apoptosis. As expected, z-VDVAD-
fmk inhibited the increase of MMP in apigenin and apigenin/
paclitaxel treated groups (Fig. 5D). Fig. 5E showed that treatment
of apigenin, paclitaxel or apigenin/paclitaxel did not alter the
mRNA level of caspase-2 indicating apigenin/paclitaxel co-
treatment only increased activation of caspase-2.
To confirm the importance of caspase-2 in apigenin/paclitaxel-
triggered mitochondrial membrane permeabilization and apopto-
sis, we perform caspase-2 over-expression and knock-down
experiments and measured AIF, Endo G and cytochrome c
releasing from mitochondrion in HeLa cells. Over-expression of
caspase-2 significantly enhanced apigenin or apigenin/paclitaxel-
induced increase of AIF, Endo G and cytochrome c in cytoplasma
Figure 3. ROS accumulation is required for apigenin/paclitaxel-triggered apoptosis A, HeLa cells were treated with ROS scavenger
NAC (100 mM) for 2 hours or not, then stained with DHE (5 mM), followed by the treatment with apigenin (15 mM) and paclitaxel
(4 nM) for 60 minutes. Cells were then collected and detected by Guava EasyCyte
TM System as described in Fig. 2A. B, HeLa cells were treated with
NAC (100 mM) for 2 hours and then incubated with apigenin (15 mM) and paclitaxel (4 nM) for 24 hours. Cell apoptosis was measured by TUNEL assay
as described in Fig. 1.
doi:10.1371/journal.pone.0029169.g003
Figure 4. Suppression of SOD activity by apigenin is associated with metal ions in HeLa cells. A, HeLa cells were treated with apigenin
(15 mM), paclitaxel (4 nM), or both of them for 30 minutes. SOD activity was measured with Cayman SOD detection kit. The experiment was
independently repeated for three times and data were shown with mean6S.D. *p,0.05 compared with control group; **p,0.01 compared with
control group. B, HeLa cells were treated with apigenin (15 mM) and paclitaxel (4 nM) for 30 minutes. Cell lysates were subjected to Western-blot
Protein to determine levels of SOD1 and SOD2. C, HeLa cells were treated with apigenin (15 mM) for 30 minutes and lysed by sonication. Cell lysates
were then incubated with CuCl2 (8 mM), ZnCl2 (8 mM) and MnCl2 (8 mM) for 30 minutes on ice. The SOD activity were measured and analyzed as
described in A. D, HeLa cells were lysed by sonication and cell lysates were then incubated with above mentioned metal ions for 30 minutes on ice.
SOD activity was measured as mentioned above. *p,0.05 compared with apigenin-treated group; **p,0.01 compared with apigenin-treated group.
doi:10.1371/journal.pone.0029169.g004
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mitochondrial fraction (Fig. 6A). As expected, caspase-2 knock-
down resulted in the opposite on apigenin or apigenin/paclitaxel
induced changes of AIF, Endo G and cytochrome c in HeLa cells
(Fig. 6A). Furthermore, as shown in Fig. 6B, over-expression of
caspase-2 apparently increased apigenin/paclitaxel-induced cleav-
age of caspase-3 and PARP and knock-down of caspase-2
inhibited such effect of apigenin/paclitaxel. We next detected cell
vitality to evaluate mediated effect of caspase-2 on apigenin/
paclitaxel triggered HeLa cell apoptosis. Over-expression of
caspase-2 caused about 10% decrease of cell vitality both in
apigenin and co-treatment groups, and caspase-2 silence signifi-
cantly increased cell vitality. However, there was no significant
change in paclitaxel treated groups no matter whether caspase-2
was over-expressed or down-expressed. Combined, the above data
suggested that caspase-2 did play an important role in apigenin/
paclitaxel induced apoptosis of HeLa cells.
Discussion
It has been well recognized that apigenin and many other
flavonoids act as anti-oxidants. Their ability to scavenge ROS was
believed to be related with their effects on anti-cancer,
chemoprevention [41] and anti-inflammation [42]. However, up
Figure 5. Apigenin-induced ROS are required for cleavage of caspase-2, MMP and cell apoptosis. A, HeLa cells were incubated with
apigenin (15 mM)/paclitaxel (4 nM), or paclitaxel (4 nM) together with or without 1 mM DETC (an inhibitor of SOD) for 24 hours and then cells were
subjected to TUNEL assay as described previously. B, HeLa cells were pretreated with NAC (100 mM) for 2 hours, followed by the treatment with
apigenin (15 mM) and paclitaxel (4 nM) for 24 hours. Cleavage of caspase-2 was detected by Western-blot analysis with the control of b-actin. C, HeLa
cells were pretreated with z-VDVAD-fmk (25 mM), a specific inhibitor of caspase-2, and then were treated with apigenin (15 mM) and paclitaxel (4 nM)
for 24 hours. Protein levels of cleaved PARP and procaspase-3 were detected by Western-blot analysis. D, HeLa cells were pretreated with z-VDVAD-
fmk (25 mM) for 30 minutes and then were treated with apigenin (15 mM) and paclitaxel (4 nM) for 8 hours. Cells were then harvested and
mitochondrial membrane potential was detected using a Guava EasyCyte
TM MitoPotential Kit and analyzed by Guava EasyCyte
TM System. MMP was
showed as the count of depolarized cells. The experiment was independently repeated for three times and data were shown as mean6SD. **p,0.01
compared with untreated group. E, HeLa cells were incubated with apigenin (15 mM) and paclitaxel (4 nM) for 24 hours, and then cells were
subjected to RT-PCR analysis. GAPDH mRNA was used as house keeper gene.
doi:10.1371/journal.pone.0029169.g005
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PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e29169until now, only a few attentions have been paid to the pro-oxidant
effect of apigenin [22]. The reason for why flavonoids possess both
pro-oxidant and anti-oxidant capability is unclear. Some studies
suggested that it depended on the dose of flavonoids and the type
of cells [24]. Cancer cells are frequently under persistent oxidative
stress because of oncogenic stimulation, increased metabolic
activity, and mitochondrial malfunction [43,44].
In the present study, we demonstrated that apigenin potentiated
ROS accumulation in HeLa cells, which correlated closely with its
inhibitory effect on SOD activity. SODs are the only enzymes
dismuting superoxide radicals. We noticed that Zn
2+,C u
2+ and
Mn
2+ could reverse apigenin-induced suppression of SOD activity
whereas these metal ions did not affect the basal SOD activity. It
was probably that apigenin formed a stable complex with metal
ions and acted as a competitive inhibitor of SOD. More detailed
studies are needed in the future. In fact, two stable coordination
geometries of the aluminum complex of apigenin have been
identified [34].
Our study indicated that apigenin/paclitaxel-induced the
cleavage of caspase-2 in a ROS dependent manner and
consequently led to MMP which resulted in leakage of pro-
apoptotic proteins from mitochondrion, such as SMAC/DIABLO
[45,46], Htr2A/Omi [47] and cytochrome c [46]. These data was
consistent with previous studies in neuron stem cells [48], leukemia
cells [49], and MCF-7 cells (Fig. S1), which suggested ROS as a
precipitating factor in caspase-2 cleavage in these cell lines.
Numerous in vivo studies have showed that SOD could highly
express in aggressive human solid tumors [50]. It has also been
reported that MnSOD can be induced by cytotoxic drugs and this
may be related with development of drug resistance and a poor
prognosis after chemotherapy in cancer cells [51,52]. In our
current study, apigenin treatment caused the suppression of SOD,
particularly the suppression of MnSOD. On the other hand,
DETC, a well approved inhibitor of both CuZnSOD and
MnSOD enhanced paclitaxel induced apoptosis. These results
strongly suggested that SOD activity was a critical factor in
paclitaxel induced apoptosis and apigenin enhanced paclitaxel-
induced apoptosis through suppressing SOD activity.
Though it have been addressed that apigenin was a potential
inducer of intracellular oxidative stress, and apigenin-induced
production of ROS play a vital role in apoptosis signal [22], very
limited data was presented on setting apigenin as a candidate to be
used in combination with traditional anti-neoplastic agents.
Paclitaxel, a potent traditional anti-cancer drug, can cause both
mitotic arrest and apoptotic cell death [53]. However, a high dose
of paclitaxel applied clinically shows serious side effects and drug
resistance [1–5]. Our results demonstrated the synergistic effects of
apigenin and paclitaxel on promoting HeLa cell apoptosis.
Apigenin sensitized HeLa cells to paclitaxel-induced apoptosis
through suppressing MnSOD and cooperated with paclitaxel to
stimulate caspase-2 activation. The results that AIF, EndoG and
cytochrome c were releasing from mitochondrion indicates both
caspase dependent and caspase independent machineries are
working in the apigenin enhanced paclitaxel induced apoptosis.
Apigenin, as a potent natural anti-cancer compound, showed little
cytotoxicity toward non-transformed cells and possessed non-
mutagenic nature. The combination use of apigenin and paclitaxel
will greatly improve the efficiency of paclitaxel as a chemother-
apeutic drug. Reduction of the dose of paclitaxel in cancer therapy
will decrease its adverse reactions.
In conclusion, our study demonstrates that combination of
apigenin and paclitaxel possesses a more apparent anti-cancer
activity in vitro compared with each of them alone. Mechanically,
apigenin suppresses the activity of SOD to lead cancer cells
sensitive to cytotoxity of paclitaxel. Furthermore, ROS-induced
activation of caspase-2 and depolarization of MMP participate in
apigenin and paclitaxel induced cancer cell apoptosis. Therefore,
this study indicates the synergistic anti-cancer effects of apigenin
and paclitaxel in tumor chemotherapy.
Supporting Information
Figure S1 Dot plots of annexin V/PI staining on viable versus
apoptotic of a drug resistant cell line MCF-7. Cells were either left
untreated or as previously described with 15 mM apigenin and
4 nM paclitaxel. At the indicated time of 24 hours, cells were
stained for annexin V/PI. Analyses were conducted on 5,000 cells
in each case.
(TIF)
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